| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 3.30▲ | 3.16▲ | 3.16▲ | 3.22▲ | 3.54▼ |
| MA10 | 3.19▲ | 3.15▲ | 3.15▲ | 3.22▲ | 5.11▼ |
| MA20 | 3.18▲ | 3.20▲ | 3.19▲ | 3.52▼ | 6.49▼ |
| MA50 | 3.27▲ | 3.36▼ | 3.47▼ | 5.35▼ | 21.94▼ |
| MA100 | 3.58▼ | 4.25▼ | 4.62▼ | 6.64▼ | 29.25▼ |
| MA200 | 4.93▼ | 5.83▼ | 6.13▼ | 17.39▼ | 36.00▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.039▲ | 0.028▲ | 0.039▲ | 0.111▲ | 0.591▲ |
| RSI | 65.173▲ | 57.920▲ | 55.438▲ | 28.228▼ | 25.536▼ |
| STOCH | 91.667▲ | 37.871 | 37.871 | 33.174 | 3.695▼ |
| WILL %R | 0.000▲ | 0.000▲ | 0.000▲ | -56.061 | -94.474▼ |
| CCI | 128.618▲ | 134.495▲ | 134.495▲ | 7.185 | -103.813▼ |
|
Wednesday, October 28, 2026 05:00 AM
SYDNEY, AUSTRALIA, Oct. 28, 2026 (GLOBE NEWSWIRE) -- (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage immunotherapy company targeting cancer and autoimmune diseases, today ...
|
|
Tuesday, October 13, 2026 01:00 AM
SYDNEY, AUSTRALIA, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, ...
|
|
Wednesday, September 23, 2026 03:47 AM
Detailed price information for Immutep Ltd ADR (IMMP-Q) from The Globe and Mail including charting and trades.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 29/10/26 | 3.04 | 3.55 | 3.04 | 3.33 | 14,038 |
| 28/10/26 | 3.19 | 3.46 | 3.19 | 3.32 | 29,526 |
| 27/10/26 | 3.10 | 3.30 | 3.10 | 3.15 | 13,557 |
| 26/10/26 | 3.28 | 3.28 | 3.05 | 3.10 | 26,998 |
| 23/10/26 | 3.21 | 3.23 | 3.10 | 3.20 | 7,942 |
| 22/10/26 | 3.27 | 3.27 | 3.0727 | 3.17 | 7,536 |
| 21/10/26 | 3.22 | 3.395 | 3.21 | 3.28 | 9,209 |
| 20/10/26 | 3.15 | 3.4195 | 3.15 | 3.26 | 16,369 |
| 19/10/26 | 3.29 | 3.29 | 3.13 | 3.17 | 6,783 |
| 16/10/26 | 3.27 | 3.27 | 3.18 | 3.20 | 11,868 |
|
|
||||
|
|
||||
|
|